RMC No. 17-2022 adds Molnupiravir 200 mg capsule Molnarz to the VAT-exempt COVID-19 treatment medicines list under RA 11534.

Businesses dealing in COVID-19 medicines must immediately update their VAT treatment for Molnupiravir 200 mg capsule under the brand name Molnarz. From the issuance date of RMC No. 17-2022 on January 31, 2022, this medicine is included in the updated list of VAT-exempt drugs and vaccines prescribed and directly used for COVID-19 treatment under Republic Act No. 11534, also known as the CREATE Act. Pharmacies, hospitals, clinics, distributors, importers, accountants, and tax teams should verify whether their invoicing, billing, and product classification systems properly reflect the VAT-exempt status of this specific COVID-19 medicine.

What changed under RMC No. 17-2022

RMC No. 17-2022 publishes the Department of Health endorsement updating the List of VAT-Exempt Drugs and Vaccines Prescribed and Directly Used for COVID-19 Treatment. The key update is the inclusion of Molnupiravir 200 mg capsule with the brand name Molnarz in the VAT-exempt list.

This is important because the VAT exemption is not framed as a generic exemption for all medicines, all antivirals, or all products connected with COVID-19. The specific medicine identified in the update is Molnupiravir 200 mg capsule, brand name Molnarz. Businesses should therefore avoid applying the exemption too broadly without confirming that the product being sold, purchased, imported, dispensed, billed, or reimbursed falls within the updated VAT-exempt COVID-19 medicine list.

For tax compliance purposes, the practical effect is that covered transactions involving the identified medicine should be reviewed for proper VAT classification. Sales invoices, official receipts, billing statements, inventory master files, point-of-sale systems, hospital charge codes, and accounting entries should be aligned with the updated VAT-exempt treatment.

Who is affected by the updated VAT-exempt COVID-19 medicine list

The businesses most affected are those that manufacture, import, distribute, sell, dispense, prescribe, purchase, reimburse, or account for COVID-19 medicines. This includes pharmaceutical companies, drug distributors, drugstores, hospitals, medical clinics, HMOs, corporate health providers, logistics providers handling pharmaceutical products, and corporate buyers purchasing COVID-19 treatment medicines for employee health programs.

Corporate accountants and tax managers should pay particular attention if their companies maintain product tax codes, VAT mapping tables, inventory item masters, or enterprise resource planning classifications for medicines. A product may be correctly classified medically but incorrectly treated for VAT purposes if the tax master file has not been updated after the inclusion of Molnupiravir 200 mg capsule Molnarz in the VAT-exempt list.

Hospitals and pharmacies should also coordinate internally between medical procurement, pharmacy operations, billing, and tax teams. The phrase many tax teams will search for is VAT-exempt COVID-19 medicines Philippines, Molnupiravir VAT exemption, RMC 17-2022 Molnarz, CREATE Act VAT-exempt drugs, and DOH endorsed VAT-exempt COVID-19 treatment medicines. These search terms all point to the same compliance issue: whether the specific medicine is covered by the BIR-recognized VAT exemption.

Key compliance requirement and effective date

The document is dated January 31, 2022. Businesses should treat that date as the relevant issuance date for purposes of updating internal tax references, compliance files, and product VAT classifications. The specific compliance action is to recognize that Molnupiravir 200 mg capsule, brand name Molnarz, is now included in the List of VAT-Exempt Drugs and Vaccines Prescribed and Directly Used for COVID-19 Treatment under Republic Act No. 11534.

The most important internal control is product-level verification. Tax teams should confirm the generic name, dosage form, strength, and brand name. The identified medicine is Molnupiravir 200 mg capsule, Molnarz. If a transaction involves a different medicine, a different strength, a different formulation, or another brand, the business should not automatically assume that the same treatment applies based only on a general reference to COVID-19 or antiviral medicine.

Companies should also keep a copy of the relevant BIR issuance in their tax compliance records and note the DOH endorsement as the basis for the update. This is especially important for businesses that may later need to explain why a sale, purchase, or reimbursement was treated as VAT-exempt.

Penalties and risk areas for non-compliance

RMC No. 17-2022 does not state a special penalty provision for failure to update VAT treatment. However, the absence of a special penalty does not mean the issue is commercially or tax-wise harmless. The main risk is incorrect VAT treatment, which can lead to billing disputes, customer refund issues, reconciliation problems, incorrect VAT reporting, and questions during tax review or audit.

For sellers, the risk is charging VAT on a product that should be treated as VAT-exempt, or failing to properly document why the exemption was applied. For buyers, the risk is booking or claiming VAT-related amounts based on an invoice that does not correctly reflect the updated treatment. For hospitals, clinics, and pharmacies, the risk is operational: billing systems may continue to treat the product under an outdated product tax code unless the item master file is manually reviewed and corrected.

Because the update concerns a specific medicine, compliance teams should avoid vague descriptions in internal records. References such as COVID medicine, antiviral, or treatment drug may be insufficient for clean tax documentation. The better practice is to identify Molnupiravir 200 mg capsule and the brand name Molnarz where relevant to the transaction record.

Practical steps for CFOs, accountants, pharmacies, and healthcare businesses

First, confirm whether the business sells, buys, imports, distributes, dispenses, reimburses, or records Molnupiravir 200 mg capsule under the brand name Molnarz. If yes, the tax team should check whether the product is mapped as VAT-exempt in the company’s accounting, inventory, billing, and point-of-sale systems.

Second, review invoices, receipts, charge slips, and billing templates used for the product. The VAT treatment should be consistent with its inclusion in the updated List of VAT-Exempt Drugs and Vaccines Prescribed and Directly Used for COVID-19 Treatment. Any inconsistency between the product master file and the actual invoice output should be corrected promptly.

Third, coordinate procurement and accounting. Procurement teams may be aware of the medical classification, while accounting teams may control tax codes. RMC No. 17-2022 is a reminder that tax treatment for COVID-19 medicines depends on specific inclusion in the recognized VAT-exempt list, not merely on business assumptions.

Fourth, preserve documentation. Businesses should maintain a compliance file showing that the product was included in the updated VAT-exempt list through the DOH endorsement published by RMC No. 17-2022. This will help support the company’s VAT treatment if the transaction is later reviewed by internal audit, external auditors, customers, suppliers, or tax authorities.

Finally, avoid overextension. The update covers Molnupiravir 200 mg capsule with brand name Molnarz. It should not be used as a blanket basis to classify all COVID-related medicines, medical supplies, or treatment products as VAT-exempt unless separately supported by the applicable list or issuance.

How Ablola, Saribong & Gueco can help

RMC No. 17-2022 is short, but its compliance impact is practical and immediate for businesses handling COVID-19 treatment medicines. A single product-level VAT classification error can affect invoices, customer billing, accounting records, and tax reporting. For companies in the pharmaceutical, healthcare, distribution, and corporate procurement sectors, the safest approach is to align medical, tax, and accounting records before the issue becomes an audit or customer dispute.

Ablola, Saribong & Gueco assists businesses with BIR compliance, VAT classification, tax documentation, invoicing review, healthcare and pharmaceutical regulatory issues, and practical tax risk management. For advice on RMC No. 17-2022, VAT-exempt COVID-19 medicines, CREATE Act tax exemptions, or BIR compliance for healthcare products, visit MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *